Focus Partners Wealth Cuts Holdings in Boston Scientific Corporation $BSX

Focus Partners Wealth decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 3.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 366,244 shares of the medical equipment provider’s stock after selling 13,009 shares during the quarter. Focus Partners Wealth’s holdings in Boston Scientific were worth $36,947,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at about $27,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 2.6%

NYSE BSX opened at $105.32 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The stock has a market capitalization of $156.06 billion, a PE ratio of 62.69, a price-to-earnings-growth ratio of 2.60 and a beta of 0.65. The firm has a 50 day moving average of $104.88 and a two-hundred day moving average of $102.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the business posted $0.62 EPS. The firm’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BSX. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Morgan Stanley boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, May 16th. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Barclays upped their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $117.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.